Amgen Presents Overall Survival Data From KYPROLIS ® (carfilzomib) Phase 3 ENDEAVOR Trial At 16th International Myeloma Workshop

Late-Breaking Presentation to Show Overall Survival Benefit of KYPROLIS Compared to Velcade® (Bortezomib) in Relapsed or Refractory Multiple Myeloma Patients First-and-Only Head-to-Head Study Comparing Proteasome Inhibitors to Demonstrate Statistically Significant Improved Overall Survival THOUSAND OAKS, Calif., March 3, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive results from a planned overall survival (OS) interim analysis of the Phase 3 head-to-head ENDEAVOR trial. The study met the key secondary endpoint of OS, demonstrating that patients with relapsed or refractory multiple myeloma treated with KYPROLIS® (carfilzomib) and dexamethasone (Kd) lived 7.6 months ...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news